Summary table PNG.PNG (90.65 kB)

Epi proColon® for Colorectal Cancer Screening: A Profile of Its Use in the USA

Download (90.65 kB)
online resource
posted on 19.06.2020 by Matt Shirley

Compliance with Ethical Standards

Funding The preparation of this review was not supported by any external funding.

Conflicts of interestMatt Shirley is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Diagnostic Q&A article can be found here.

Abstract
Epi proColon® is a blood-based colorectal cancer (CRC) screening test that presents a convenient, non-invasive option for CRC screening in average-risk adults aged ≥ 50 years who are otherwise non-compliant to guideline-recommended screening programs. The Epi proColon test involves the use of a real-time PCR assay to detect methylated Sept9 DNA (a biomarker for CRC) in plasma derived from a whole blood sample. Epi proColon generally performed well in prospective clinical trials, having non-inferior sensitivity for detecting CRC compared with a fecal immunochemical test (FIT). Microsimulation modeling supports annual Epi proColon testing, as for FIT. Although the Epi proColon test specificity is lower than that of a FIT, the Epi proColon test may be useful for improving participation and compliance in CRC screening, as evidenced in a small randomized controlled clinical trial which showed that uptake of an offer of an Epi proColon blood test was significantly higher than that for a FIT in subjects who were overdue for CRC screening.

© Springer Nature Switzerland AG 2020


History

Licence

Exports